



Figure 1: Diagram of high-throughput screen workflow with the initial cohort of epigenetic compounds. Three human ERMS cell lines, and one murine ERMS tumor-derived cell line were screened with 207 compounds. Hits reduced viability in at least two cell lines, with therapeutic range $<1 \mu\text{M}$. Further triaging included reviewing literature and clinical trials.